Drugs / GEM00220
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04961658 | Aug 2021 → Aug 2023 | infectious disease with sepsis | Northern Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEM00220 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04961658 ↗ |
| Route | Intravenous | “Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion” NCT04961658 ↗ |